I Know First Review: November 24th 2015

I Know First Review

The stocks selected here are the top performing stocks from I Know First: Biotech Stocks Package forecast for the last 1 month.

This forecast is part of the Industry package, as one of I Know First’s quantitative investment solutions. The “I Know First Average” return for the long position was 18.86% over the 1 month period, a significant difference when comparing the S&P 500’s return of 1.66% over the same time period.

i know first review


oxigene_logoSignal: 175.85

Predictability: 0.24

Return: -3.88%

OXiGENE, Inc. is a clinical-stage, biopharmaceutical company developing therapeutics primarily to treat cancer. On November 10th, the company has announced its third quarter financial results. The company has recently started phase 1b/2 clinical trial of OXi4503 for leukemia treatment.

oncogenexSignal: 64.74

Predictability: 0.32

Return: 11.16%

OncoGenex Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of new therapies that address treatment resistance in cancer patients. The company’s stock has been doing really well recently having had a 10.7% rise in the past 4 weeks. Overall it has risen 13.27% since late April.

heron theraeutics


Signal: 50.52

Predictability: 0.28

Return: 32.25%

Heron Therapeutics, Inc. is a biotechnology company. The Company uses its technology to develop products to address unmet medical needs. Its Biochronomer polymer-based drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals. In October the company welcomed its new senior VP and Chief Medical Officer Clendeninn, M.D., Ph.D with over 25 years of experience in the industry.


Signal: 39.32

Predictability: 0.35

Return: 52.70%

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of unique ribonucleic acid (RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. Analysts are feeling largely positive about prospects of company’s new drug eteplirsen. It was considered a stronger drug than rival BioMarin’s despite a smaller dataset.



Signal: 26.96

Predictability: 0.19

Return: -27.71%

CTI BioPharma Corp. (CTIC), formerly Cell Therapeutics, Inc., is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers. It was announced on November 20th that Louis A Bianco , EVP, Finance & Administration has sold 15,000 shares on November 19th. The shares were sold at 1.13 per share.

Sucampo-Pharmaceuticals-Inc.Signal: 23.79

Predictability: 0.27

Return: 1.38%

Sucampo Pharmaceuticals, Inc. is a global biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic, and oncology-based inflammatory disorders. It generates revenue from product royalties, development milestone payments, product sales and clinical development activities. At the end of September the company has reported a year-over-year growth of 6%, which might have had a positive effect on SCMP stock in in the past two months.

nwbio_logo_285x93Signal: 23.13

Predictability: 0.15

Return: 3.50%

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. COmpany shares have appreciated 5.51% last week but had an overall decrease of 6.81% in the past 4 weeks.
FOLDSignal: 21.39

Predictability: 0.25

Return: 80.34%

Amicus Therapeutics, Inc. (FOLD), the American biopharmaceutical company only went public as little as 8 years ago and is already a dominant player in the biotech field. Although the company announced a delay to its timeline for filing for approval of its Fabry disease therapy, Galafold, in the United States it has still managed to leave investors optimistic. The Galafold drug is extremely powerful and much more efficient that the current drugs tackling the disease, moreover the the company is set to clarify the timing of an FDA application soon


Signal: 20.39

Predictability: 0.2

Return: 21.59%

ImmunoGen, Inc. (ImmunoGen) is a clinical-stage biotechnology company focused on the development of targeted anticancer therapeutics. The Company’s clinical and preclinical product candidates are antibody-drug conjugates (ADCs), which is a type of medicine that uses a monoclonal antibody to deliver a therapeutic agent to targeted cells. On Wednsesday November 25th the stock has went up 6.66% to $13.70, being one of the biggest gainers of Russell 2000.

neurocrine-NBIX-logoSignal: 13.44

Predictability: 0.27

Return: 15.53%

Neurocrine Biosciences, Inc. (NBIX) is engaged in the development of pharmaceutical products focused on neurological and endocrine based diseases and disorders.The Business ‘s two lead late-stage clinical programs are elagolix, a gonadotropin releasing hormone (NASDAQ:NBIX) antagonist for women’s well-being that’s partnered with AbbVie Inc. (AbbVie), and a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. The company shares have rallied 172.11% from its 1 Year high price.